Evidence map›Paper›PMID 24453174›Full record

ArticlePathogens and disease2014

Mycobacterium tuberculosis pellicles express unique proteins recognized by the host humoral response.

Patrick W Kerns, David F Ackhart, Randall J Basaraba, Jeff G Leid, Mark E Shirtliff

Open access · bronzeAbstract read
In one paragraph

Article in Pathogens and disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Biofilm Associated Persistence and Drug Tolerance in Mycobacteria Within Host Microenvironments.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.International journal of molecular sciences · 2024
    Review
  7. ImmunoTargets and therapy · 2024
    Review
  8. mSystems · 2023
    Article
  9. Article
  10. Article
  11. Role of theFrontiers in genetics · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Advance in Research onFrontiers in microbiology · 2018
    Article
  16. Article
  17. Proteomics progresses in microbial physiology and clinical antimicrobial therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Patrick W KernsGraduate Program in Molecular Microbiology and Immunology, University of Maryland, Baltimore, Baltimore, MD, USA.
David F Ackhart
Randall J Basaraba
Jeff G Leid
Mark E Shirtliff
Colorado State University · USUniversity of Maryland, Baltimore · USW. L. Gore & Associates (United States) · US

Funding

TRAINING IN OROFACIAL BIOLOGY AND NEUROSCIENCET32DE007309 · NIDCR · UNIVERSITY OF MARYLAND BALTIMORE · PI GORDON, SHARON M. · 1997 to 2012
$6.8M
Disrupting Biofilm Formation to Improve TB Drug TreatmentR01AI106733 · NIAID · COLORADO STATE UNIVERSITY · PI BASARABA, RANDALL J · 2013 to 2017
$2.3M
Staphylococcus aureus biofilms: in vitro and in vivo studiesR01AI069568 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SHIRTLIFF, MARK E · 2007 to 2011
$2.1M
NIAID NIH HHS 1R01AI106733-01NIAID NIH HHS AI069568NIAID NIH HHS R01 AI069568NIAID NIH HHS R01 AI069568-02NIAID NIH HHS R01 AI106733NIDCR NIH HHS 2T32 DE007309NIDCR NIH HHS T32 DE007309
6 · The paper itself

Abstract

Mycobacterium tuberculosis (MTB) causes both acute and chronic infections in humans characterized by tolerance to antibiotics and reactivation to cause secondary tuberculosis. These characteristics have led to renewed interest in the in vitro pellicle, or biofilm mode of growth, where bacteria grow to produce a thick aggregate at the air-liquid interface and exhibit increased phenotypic resistance to antibiotics. We infected guinea pigs with the virulent H37Rv strain of MTB for 60 days at which point we collected blood. To identify antigenic proteins, membrane protein extracts of MTB H37Ra pellicles and shaken cultures grown for 3, 5, or 7 weeks were probed with the infected animals' sera after the proteins were separated by two-dimensional gel electrophoresis (2DGE). Antigenic proteins were then identified using MALDI-TOF/TOF mass spectrometry peptide mass fingerprinting. Antigenic pellicle proteins were compared across the three timepoints to identify those that were produced consistently during pellicle growth. They were also compared to those membrane proteins identified from harvested shaken cultures to determine pellicle-specific vs. universally expressed proteins. Using this technique, we identified 44 distinct antigenic proteins, nine of which were pellicle-specific. The sequence of antigenic pellicle-specific proteins was checked for sequence conservation across 15 sequenced MTB clinical isolates, three other members of the MTB complex, as well as M. avium and M. smegmatis. The antigenic pellicle-specific protein Rv0097 was found to have very high sequence conservation within the MTB complex but not with related mycobacteria, while FabG4 was highly conserved in all mycobacteria analyzed. These conserved pellicle-specific proteins represent targets for the development of future diagnostic tests and vaccines.

Indexed as

Immunity, HumoralAnimalsBacterial Outer Membrane ProteinsBacterial ProteinsBiofilmsConserved SequenceDisease Models, AnimalFemaleGene ExpressionGuinea PigsHost-Pathogen InteractionsHumansMycobacterium tuberculosisTuberculosisBacterial Outer Membrane ProteinsBacterial Proteinsbiofilmhumoralpellicleproteomicstuberculosis

Identifiers

PMID24453174
PMCPMC4363115
OpenAlexW2169109503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.